TheLife Sciencesteam advised Replicate Bioscience on a multi-year research collaboration with Novo Nordisk. This collaboration unites Replicate's novel srRNA platform with Novo Nordisk's deep therapeutic knowledge and drug development expertise to treat obesity, type 2 diabetes and other cardiometabolic diseases.
Under the terms of the agreement, Novo Nordisk and Replicate will collaborate on certain targets for cardiometabolic diseases. Novo Nordisk will receive an exclusive, worldwide license to use Replicate's srRNA platform to develop certain targets for cardiometabolic diseases and commercialize lead programs resulting from the collaboration. Replicate will receive research funding and is eligible to receive up to $550 million from Novo Nordisk. This includes an up-front cash payment and potential milestone payments. Replicate is also eligible to receive tiered royalties on future product sales as part of the multi-year deal.
Replicate Bioscienceis a clinical-stage company amplifying the power of RNA therapeutics by pioneering its novel self-replicating RNA (srRNA) technology to overcome the shortcomings of existing RNA approaches, with potential improvements in bioactivity, induction of more potent immune responses, and improved therapeutic index. RBI-4000, the company's clinical-stage srRNA rabies vaccine, has demonstrated protective levels of immunity at doses lower than any other reported RNA-based vaccine in Phase 1 trials. Funded by Apple Tree Partners, Replicate is advancing a robust pipeline of srRNA vaccines and therapeutics, fueled by its proprietary library of customizable viral vectors. With deep expertise in srRNA and end-to-end development capabilities, Replicate is uniquely positioned to expand the reach of RNA treatments toward widespread use in infectious disease, immunology, immuno-oncology and more.
The Goodwin deal team was led bySarah Solomon,Sarah StoiberandAlexandra Haas.
For more information on the deal, please read thepress releaseand see coverage inFierce Biotech,Endpoints News,MedCity News, andPharmaceutical Technology.